Related Experiment Video

Updated: Jun 4, 2026

Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy

Johanna Savikko1, Jukka M Rintala, Sini E Rintala

  • 1Transplantation Laboratory, University of Helsinki, and Helsinki University Central Hospital, Helsinki, Finland. johanna.savikko@helsinki.fi

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|February 3, 2011
PubMed
Abstract

Insights

Early short-term imatinib treatment effectively prevented chronic allograft nephropathy (CAN) in kidney transplants. This suggests platelet-derived growth factor (PDGF) inhibition is key to stopping CAN development.

Area of Science:

  • Nephrology
  • Transplantation Immunology
  • Pharmacology

Background:

  • Chronic allograft nephropathy (CAN) is a common complication after kidney transplantation.
  • Platelet-derived growth factor (PDGF) drives the cellular changes seen in CAN.
  • Investigating early intervention to prevent CAN is crucial.

Purpose of the Study:

  • To determine if short-term inhibition of PDGF with imatinib can prevent CAN development.
  • To assess the impact of early imatinib treatment on kidney graft histology and function.

Main Methods:

  • Rat kidney allografts (Dark-Agouti to Wistar-Furth) and syngenic controls were used.
  • Allografts received cyclosporine immunosuppression; one group also received imatinib for 30 days.
  • Serum creatinine and graft histology were assessed 90 days post-transplantation.

Main Results:

  • Early imatinib treatment significantly prevented CAN development compared to controls.
  • Imatinib inhibited fibrogenic growth factor pathways and inflammatory responses.
  • Creatinine levels were significantly lower in imatinib-treated allografts.

Conclusions:

  • Short-term imatinib therapy is sufficient to prevent CAN, highlighting the role of early PDGF in its pathogenesis.
  • These preclinical findings support further investigation in human kidney transplant patients.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...